Literature DB >> 12067968

3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules.

Andreas K Buck1, Holger Schirrmeister, Martin Hetzel, Mareike Von Der Heide, Gisela Halter, Gerhard Glatting, Torsten Mattfeldt, Florian Liewald, Sven N Reske, Bernd Neumaier.   

Abstract

We investigated whether uptake of the thymidine analogue 3-deoxy-3-[(18)F]fluorothymidine ([(18)F]FLT) reflects proliferation in solitary pulmonary nodules (SPNs). Thirty patients with SPNs were prospectively examined with positron emission tomography. Standardized uptake values were calculated for quantification of FLT uptake. Histopathology revealed 22 malignant and 8 benign lesions. Proliferation was evaluated by Ki-67 immunostaining and showed a mean proliferation fraction of 30.9% (range, 1-65%) in malignant SPNs and <5% in benign lesions. Linear regression analysis indicated a significant correlation between FLT-standardized uptake values and proliferative activity (P < 0.0001; r = 0.87). FLT uptake was specific for malignant lesions and may be used for differential diagnosis of SPNs, assessment of proliferation, and estimation of prognosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067968

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  62 in total

Review 1.  Imaging of lung cancer in the era of molecular medicine.

Authors:  Mizuki Nishino; David M Jackman; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson; Annick D Van den Abbeele
Journal:  Acad Radiol       Date:  2011-01-28       Impact factor: 3.173

2.  Molecular imaging in oncology by means of nuclear medicine: fact or fiction?

Authors:  Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

3.  Noninvasive imaging of endogenous neural stem cell mobilization in vivo using positron emission tomography.

Authors:  Maria Adele Rueger; Heiko Backes; Maureen Walberer; Bernd Neumaier; Roland Ullrich; Marie-Lune Simard; Beata Emig; Gereon Rudolf Fink; Mathias Hoehn; Rudolf Graf; Michael Schroeter
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

4.  Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer.

Authors:  Wenfeng Yang; Yongming Zhang; Zheng Fu; Jinming Yu; Xiaorong Sun; Dianbin Mu; Anqin Han
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

5.  Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.

Authors:  Heiko Schöder; Andrew D Zelenetz; Paul Hamlin; Somali Gavane; Steven Horwitz; Matthew Matasar; Alison Moskowitz; Ariela Noy; Lia Palomba; Carol Portlock; David Straus; Ravinder Grewal; Jocelyn C Migliacci; Steven M Larson; Craig H Moskowitz
Journal:  J Nucl Med       Date:  2015-12-30       Impact factor: 10.057

6.  From anatomical to biological target volumes: the role of PET in radiation treatment planning.

Authors:  D A X Schinagl; J H A M Kaanders; W J G Oyen
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

Review 7.  [18F]FLT-PET in oncology: current status and opportunities.

Authors:  Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 9.236

8.  Early response assessment in prostate carcinoma by ¹⁸F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumour models.

Authors:  Nobuyuki Oyama; Yoko Hasegawa; Yasushi Kiyono; Masato Kobayashi; Yasuhisa Fujibayashi; Datta E Ponde; Carmen Dence; Michael J Welch; Osamu Yokoyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-29       Impact factor: 9.236

9.  Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?

Authors:  Sven N Reske; Sandra Deisenhofer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

10.  Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer.

Authors:  D L Francis; D Visvikis; D C Costa; T H A Arulampalam; C Townsend; S K Luthra; I Taylor; P J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-09       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.